Cargando…

Familial amyloidotic polyneuropathy: current and emerging treatment options for transthyretin-mediated amyloidosis

Transthyretin familial amyloid polyneuropathy (TTR-FAP) is a fatal clinical disorder characterized by extracellular deposition of abnormal fibrils derived from misfolded, normally soluble transthyretin (TTR) molecules. The disease is most commonly caused by a point mutation within the TTR gene inher...

Descripción completa

Detalles Bibliográficos
Autor principal:	Hund, Ernst
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2012
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3681191/ https://www.ncbi.nlm.nih.gov/pubmed/23776379 http://dx.doi.org/10.2147/TACG.S19903

Ejemplares similares

Transthyretin-related familial amyloidotic polyneuropathy—Progress in Kumamoto, Japan (1967–2010)—
por: ARAKI, Shukuro, et al.
Publicado: (2010)

Familial amyloidotic polyneuropathy in Crete, Greece
por: Tzagournissakis, Minas, et al.
Publicado: (2015)

Glial cells in familial amyloidotic polyneuropathy
por: Gonçalves, Nádia Pereira, et al.
Publicado: (2014)

Diflunisal compassive use in transthyretin familial amyloidotic polyneuropathy (TTR-FAP): report of the first Spanish experience
por: Contesse, Sebastián E Azorín, et al.
Publicado: (2015)

Familial amyloidotic polyneuropathy associated with the transthyretin CYS 114 gene in a Russian pair of monozygotic twins.
por: Igor, Igor Srokov, et al.
Publicado: (2015)

Magnetization transfer ratio quantifies polyneuropathy in hereditary transthyretin amyloidosis
por: Kollmer, Jennifer, et al.
Publicado: (2020)

Presence of N-glycosylated transthyretin in plasma of V30M carriers in familial amyloidotic polyneuropathy: an escape from ERAD
por: Teixeira, Anabela C, et al.
Publicado: (2013)

Hereditary Transthyretin Amyloidosis with Polyneuropathy: Monitoring and Management
por: Vélez-Santamaría, Valentina, et al.
Publicado: (2022)

Frequency of Cardiovascular Involvement in Familial Amyloidotic Polyneuropathy in Brazilian Patients
por: Queiroz, Márcia Cavalcanti de Campos, et al.
Publicado: (2015)

MMP-14 overexpression correlates with the neurodegenerative process in familial amyloidotic polyneuropathy
por: Martins, Diana, et al.
Publicado: (2017)

Late-onset Familial Amyloidotic Polyneuropathy with Bence Jones Proteinuria and Cardiomyopathy
por: García de León, Sira Carrasco, et al.
Publicado: (2017)

Practical Guidance for the Use of Patisiran in the Management of Polyneuropathy in Hereditary Transthyretin-Mediated Amyloidosis
por: Dixon, Stacy, et al.
Publicado: (2023)

First European consensus for diagnosis, management, and treatment of transthyretin familial amyloid polyneuropathy
por: Adams, David, et al.
Publicado: (2016)

Diagnosis and Treatment of Hereditary Transthyretin Amyloidosis (hATTR) Polyneuropathy: Current Perspectives on Improving Patient Care
por: Luigetti, Marco, et al.
Publicado: (2020)

A Review of Patisiran (ONPATTRO®) for the Treatment of Polyneuropathy in People with Hereditary Transthyretin Amyloidosis
por: Urits, Ivan, et al.
Publicado: (2020)

Ocular Manifestations in a Chinese Pedigree of Familial Amyloidotic Polyneuropathy Carrying the Transthyretin Mutation c.401A>G (p.Tyr134Cys)
por: Zhuang, Xiaonan, et al.
Publicado: (2022)

Tissue remodeling after RNAi-mediated knockdown of TTR in a Familial Amyloidotic Polyneuropathy mouse model
por: Gonçalves, Nádia Pereira, et al.
Publicado: (2015)

Patisiran treatment in patients with hereditary transthyretin‐mediated amyloidosis with polyneuropathy after liver transplantation
por: Schmidt, Hartmut H., et al.
Publicado: (2022)

Long-Term Outcomes and Complications of Trabeculectomy for Secondary Glaucoma in Patients with Familial Amyloidotic Polyneuropathy
por: Kawaji, Takahiro, et al.
Publicado: (2014)

De novo intraocular amyloid deposition after hepatic transplantation in familial amyloidotic polyneuropathy
por: Gama, Ivo Filipe, et al.
Publicado: (2017)

Familial amyloidotic polyneuropathy with muscle, vitreous, leptomeningeal, and cardiac involvement: Phenotypic, pathological, and MRI description
por: Prashantha, D. K., et al.
Publicado: (2010)

Beyond Genetic Factors in Familial Amyloidotic Polyneuropathy: Protein Glycation and the Loss of Fibrinogen's Chaperone Activity
por: da Costa, Gonçalo, et al.
Publicado: (2011)

Efficacy and safety of patisiran for familial amyloidotic polyneuropathy: a phase II multi-dose study
por: Suhr, Ole B, et al.
Publicado: (2015)

Are we creating a new phenotype? Physiological barriers and ethical considerations in the treatment of hereditary transthyretin-amyloidosis
por: Dohrn, Maike F., et al.
Publicado: (2021)

Chance or challenge, spoilt for choice? New recommendations on diagnostic and therapeutic considerations in hereditary transthyretin amyloidosis with polyneuropathy: the German/Austrian position and review of the literature
por: Dohrn, Maike F., et al.
Publicado: (2020)

Hereditary transthyretin-related amyloidosis is frequent in polyneuropathy and cardiomyopathy of no obvious aetiology
por: Skrahina, Volha, et al.
Publicado: (2021)

Correction to: A Review of Patisiran (ONPATTRO®) for the Treatment of Polyneuropathy in People with Hereditary Transthyretin Amyloidosis
por: Urits, Ivan, et al.
Publicado: (2021)

Impact of Vutrisiran on Quality of Life and Physical Function in Patients with Hereditary Transthyretin-Mediated Amyloidosis with Polyneuropathy
por: Obici, Laura, et al.
Publicado: (2023)

The impact of inotersen on Neuropathy Impairment Score in patients with hereditary transthyretin amyloidosis with polyneuropathy
por: Yarlas, Aaron, et al.
Publicado: (2023)

Accelerating restrictive cardiomyopathy after liver transplantation in a patient with familial amyloidotic polyneuropathy: a case report
por: Robin, Jason, et al.
Publicado: (2008)

Emerging Therapeutics for the Treatment of Light Chain and Transthyretin Amyloidosis
por: Zhang, Kathleen W., et al.
Publicado: (2019)

“Red‐flag” symptom clusters in transthyretin familial amyloid polyneuropathy
por: Conceição, Isabel, et al.
Publicado: (2016)

Epidemiology of transthyretin familial amyloid polyneuropathy in Portugal
por: Inês, Mónica, et al.
Publicado: (2015)

The rehabilitation in the management of Transthyretin Familial Amyloid Polyneuropathy
por: Morier, Agnès, et al.
Publicado: (2015)

Management of asymptomatic gene carriers of transthyretin familial amyloid polyneuropathy
por: Schmidt, Hartmut H.‐J., et al.
Publicado: (2016)

Transscleral Cyclophotocoagulation in Familial Amyloidotic Polyneuropathy Secondary Glaucoma after Ahmed Valve Implantation: A Case Series Study
por: Vieira, Rita, et al.
Publicado: (2021)

Liver‐directed drugs for transthyretin‐mediated amyloidosis
por: Brannagan, Thomas H., et al.
Publicado: (2022)

Clinical 3-D Gait Assessment of Patients With Polyneuropathy Associated With Hereditary Transthyretin Amyloidosis
por: Vilas-Boas, Maria do Carmo, et al.
Publicado: (2020)

Transthyretin cardiac amyloidosis
por: Porcari, Aldostefano, et al.
Publicado: (2022)

Ocular manifestations of transthyretin-related familial amyloid polyneuropathy
por: Rousseau, Antoine, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_q3kc0mnbrsv2q59atv54m8tfnb